Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OxHARP: Sildenafil in Small Vessel Disease
NCT03855332Phase 2Completed
- Sponsor
- University of Oxford
- Start
- Jul 2019
- Primary completion
- Dec 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of sildenafil in Cerebral Small Vessel Disease (CSVD) (3 arms), sponsored by University of Oxford. Primary endpoint: Middle cerebral arterial pulsatility index at 3 weeks. Started Jul 2019; status: completed.
02
Drugs
sildenafil
03
Conditions
Cerebral Small Vessel Disease (CSVD)
Beyond the preview
Go deeper on NCT03855332.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03855332.